Implementing Bispecific Treatments


Panelists explore the challenges, implementations, and decision-making processes surrounding bispecific treatments in diffuse large B-cell lymphoma (DLBCL).

This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA.

In this segment, Mahmoudjafari and Mancini discuss the implementation of step-up dosing for bispecific therapies in lymphoma patients. Mancini details the multifaceted approach at his institution, including policy development, patient guidelines, referral processes, and outpatient monitoring. He emphasizes the importance of education and collaboration with health care providers overseeing chimeric antigen receptor (CAR) T-cell therapies.

Ali shares insights into the administration of bispecifics at his center, currently using inpatient ramp-up followed by outpatient maintenance. The discussion delves into considerations for decision-making when selecting bispecifics, highlighting institutional preferences, insurance coverage, and the availability of CAR T-cell therapy options. The conversation provides valuable perspectives on the challenges and preparations involved in implementing bispecific therapies, emphasizing the evolving landscape of lymphoma treatment.

This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.